VRTX

3 Biotech Stocks With Great Potential in 2014

moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Vertex is hiring next, click here to view […]

As Competitors Pursue Alternatives Medgenics’ INFRADURE Gains Prominence for its Potential to Treat Hepatitis

[ACN Newswire] – Medgenics’ (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Vertex is hiring next, click here to view […]

PropThink: Does Achillion Have a Place in the HCV Market of the Future?

[ACN Newswire] – By Ivan DeryuginThe biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation of drugs for a market stand to gain … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Lightweight Contender ACHN Declines on Gilead’s Latest Hepatitis Data

[ACN Newswire] – By Jake KingWith Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively at … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Vertex Earnings Demonstrate Incivek’s Short-Lived Stardom

[ACN Newswire] – By Jake KingHepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, it may soon … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

[ACN Newswire] – By David SobekIn November of 2011, Gilead (NASDAQ:GILD) announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO John Martin noted , the … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Abbot’s Impressive HCV Data Continues the Trend; Everyone’s Got a Candidate

[ACN Newswire] – By Jake KingDevelopers of potential Hepatitis C (HCV) treatments are among the most-traded in the healthcare industry on Monday, following an announcement from Abbot Laboratories (NYSE:ABT) that a combinations … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Vertex Drops One Drug, Advances Another as HCV Segment Heats Up

[ACN Newswire] – By Jake KingOn Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that while it would be advancing its developmental Hepatitis C (HCV) treatment, ALS-2200, into Phase II testing, ALS-2158 didn’t make … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]